Biotech Values

[drbio45]

http://phx.corporate-ir.net/phoenix.zhtml?c=117573&p=irol-newsArticle&t=Regular&id=60612...

3692 for 6/30 to 08/13

http://phx.corporate-ir.net/phoenix.zhtml?c=117573&p=irol-newsArticle&t=Regular&id=63308...

4479 for 08/13-09/30

http://phx.corporate-ir.net/phoenix.zhtml?c=117573&p=irol-newsArticle&t=Regular&id=64803...

4374 for 9/30 to 11/15

It would have been nice if the sales for the newest period
was greater than the prior one but the six week number may not be the greatest measure because there are 13 weeks in a quarter

they will be filing the snda for xyrem in narcolepsy this month or next and this will add to off label use so sales should go up nicely.

The market cap is only 120 million. the risk reward is very positive for this stock.